At the end of today's A-share trading, it once again broke the hearts of investors and double dived again! It just fell below 3000 points, and today it fell below 2900 points. Next, we need to guard 2800 points together! From the perspective of music, this is the opportunity for A-Shares to copy the bottom every day
The most ironic thing is that China Securities Co.Ltd(601066) teacher just said that 2900 was the golden pit at noon and dived like this in the afternoon. I hope this is the last big pit. The investors are too bitter.
lost 2900
guard 2800
The two integer levels of 3000 and 2900 have been broken one by one by the air force. On April 26, the market soared all day, fell back and dived in the afternoon. The three indexes hit a new low, and the Shanghai Composite Index fell behind the integer level of 2900. On the disk, less than 10 sectors rose, mainly consumer medicine. In terms of decline, brokerage stocks fell sharply today, dragging down the index. Overall, individual stocks fell more and rose less. More than 3900 individual stocks in the two cities fell, and nearly 300 stocks fell by the limit or more than 10%.
The total turnover of the two cities was 838.8 billion yuan, and the net purchase of northbound funds was 1.543 billion yuan.
The textile and garment sector saw a decline in the limit. More than 30 shares, including Hunan Mendale Hometextile Co.Ltd(002397) , Fujian Fynex Textile Science & Technology Co.Ltd(600493) , Zhejiang Red Dragonfly Footwear Co.Ltd(603116) , Shanghai Sanmao Enterprise (Group) Co.Ltd(600689) and so on, fell by the limit or more than 10%.
Cyclical stocks such as coal, oil and gas and non-ferrous metals fell sharply again, and more than 20 stocks such as Liaoning Energy Industry Co.Ltd(600758) , Shanxi Coking Co.Ltd(600740) , China Coal Xinji Energy Co.Ltd(601918) , Xinjiang Zhundong Petroleum Technology Co.Ltd(002207) fell by the limit.
Under the guidance of the financial management department, the rescue of problematic real estate enterprises has been stepped up, and the real estate sector has strengthened.
Omicron mutant covid-19 virus inactivated vaccine obtained the clinical approval of the State Food and Drug Administration
On April 26, 2022, the covid-19 virus inactivated vaccine of Sinopharm China biological Omicron mutant (hereinafter referred to as Austrian strain) obtained the clinical approval of the State Food and drug administration.
Sinopharm China Bio introduced the Omicron variant strain from the University of Hong Kong for the first time on the basis of the prototype strain covid-19 inactivated vaccine listed in the early stage and the research and development of beta and delta variant inactivated vaccine. On December 9, 2021, Sinopharm China Bio quickly launched the research and development of Austrian strain inactivated vaccine.
According to the guiding principles and R & D strategy of the improved covid-19 vaccine of the State Food and drug administration, Sinopharm China bioavailability's new P3 high-level biosafety laboratory has completed the screening, passage and amplification of Austrian virus species, established a three-level virus seed bank, and completed process verification, preparation of multiple batches of large-scale products, quality standard research, in vivo safety evaluation of animals and immunogenicity research, The results showed that Austrian covid-19 inactivated vaccine could produce high titer neutralizing antibodies against Austrian strain and many variants. On March 3, 2022, Beijing Institute of biological products and Wuhan Institute of biological products determined the clinical scheme and relevant details with Hong Kong research institutions. On March 26 and 30, they obtained the verification qualification report of China Institute of drug and food control respectively. On April 1, they submitted clinical application materials to the Hong Kong Department of health, obtained ethical approval on April 12 and clinical research approval on April 13, It has become the first inactivated vaccine of Omicron strain approved for clinical use in the world.
At the same time, Sinopharm China biological began to submit Chinese clinical application materials to the drug evaluation center of the State Food and Drug Administration on a rolling basis from January 26 to start the technical review.
On April 26, the inactivated vaccine of Omicron variant covid-19 virus of Beijing Institute of biological products of China obtained the clinical approval issued by the State Food and Drug Administration of China. In the form of randomized, double-blind and cohort study, China biology will conduct a sequential immune clinical study among people aged 18 and over who have completed 2 or 3 doses of covid-19 vaccine to evaluate the safety and immunogenicity of inactivated covid-19 virus vaccine of Omicron variant.
Shouldering the political and social responsibilities of central enterprises, China biology independently developed four covid-19 diagnostic reagents, four covid-19 specific therapeutic drugs and four covid-19 vaccines in three technical routes around the three fields of "diagnosable, treatable and preventable", which fully played the role of the national team, main force and pillar of the pharmaceutical industry and created a strategic scientific and technological force to maintain national biosafety, It has promoted China's vaccines and therapeutic drugs to benefit the Chinese people and the world.
Affected by the news, China National Medicines Corporation Ltd(600511) straight limit.
However, it should be noted that according to the relevant regulatory requirements of the state, the vaccine sales have implemented the one vote system, China National Medicines Corporation Ltd(600511) do not distribute vaccines, and do not have a direct vaccine business relationship with China biology. The main business of the company is pharmaceutical wholesale, which does not involve vaccine R & D and production. The main business of the company has not changed significantly.
gold pit smashed
bull market flagmen fell across the board
The brokerage sector fell across the board, and many stocks fell by the limit China Securities Co.Ltd(601066) afternoon flash collapse, the end of the trading once fell to the limit.
At noon, China Securities Co.Ltd(601066) chief strategic analyst said that after comprehensive evaluation, we believe that the gold pit near 2900 is this year's gold pit. Investors need to grasp the growth opportunity of the market at the low level, and then consider the recovery of the market after the recovery of the market.
peripheral markets
European stocks collectively opened higher, with Germany's DAX30 index up 1.19%, Britain's FTSE 100 index up 1.00%, France's CAC40 index up 0.84% and Europe's Stoxx 50 index up 1.12%. As of press time, the increase fell
US stocks are also diving in front of the market.
Hong Kong stocks also plunged.
Will it be better for everyone to dive together?
In addition, the Hong Kong stock dream world collapsed by 70%, and the decline narrowed to about 40% as of press time.
In fact, this company has some connections with the gambling king's son he Youjun. Chuang mengtiandi is a Hong Kong listed company. Since May 2018, he Youjun, the son of the gambling king, has served as the chief marketing officer of chuangmengtiandi, responsible for marketing and promotion, E-sports related businesses and expanding real-world games.
In 2018, dreamworld went to Hong Kong for listing. The star shareholders include Tencent Holdings (00700. HK) and he Youjun, the son of "Macao gambling king". The chairman of the board of directors of chuangmengtiandi is Chen Xiangyu, holding 19.13%.
Born in 1995, he Youjun joined Chuang mengtiandi in mid-2017 and assumed the post of CMO (Chief Marketing Officer). His mother, Ms. Liang Anqi's Vigo global, entered in the pre IPO round and held 1.11% of Chuang mengtiandi.
